Cancer revoked: oncogenes as therapeutic targets
Top Cited Papers
- 1 May 2003
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 3 (5) , 375-379
- https://doi.org/10.1038/nrc1070
Abstract
Recent findings show that even the brief inactivation of a single oncogene might be sufficient to result in the sustained loss of a neoplastic phenotype. It is therefore possible that the targeted inactivation of oncogenes could be a specific and effective treatment for cancer. So why does oncogene inactivation cause tumour regression and will this be a generally successful approach for the treatment of human neoplasia?Keywords
This publication has 37 references indexed in Scilit:
- Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesisGenes & Development, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic ProgressionCell, 2002
- DNMT1 and DNMT3b cooperate to silence genes in human cancer cellsNature, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Disabling Abl—Perspectives on Abl kinase regulation and cancer therapeuticsCancer Cell, 2002
- Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription FactorScience, 2002
- Reversible Activation of c-Myc in SkinMolecular Cell, 1999
- Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from GrapesScience, 1997
- Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice.Proceedings of the National Academy of Sciences, 1996